In addition, therapeutic strategies targeting CTGF, such as monoclonal antibodies, have shown promising results in vitro and have been tested in large randomized clinical trials for idiopathic pulmonary fibrosis. Here, CCN2 is linked to idiopathic pulmonary fibrosis.